On July 25, SELLAS Life Sciences Group Inc. fell 8.35% in regular trading, trading at $11.29/share, with Turnover of $53.60 million.
Within the Biotechnology sector where SELLAS Life Sciences Group Inc. belongs, among individual stocks, AbbVie up 0.58%, Amgen up 1.17%, Gilead Sciences down 0.86%, Vertex Pharmaceuticals up 0.92%, Argenx SE down 1.3%.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for various cancer indications. Its lead product candidate is galinpepimut-S (GPS), currently in Phase 3 clinical trials for the treatment of acute myeloid leukemia.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments